X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4) 4
antineoplastic agents - therapeutic use (3) 3
hematology (3) 3
medical and health sciences (3) 3
medicin och hälsovetenskap (3) 3
antineoplastic agents - adverse effects (2) 2
benzamides (2) 2
chronic myelogenous leukemia (2) 2
clinical medicine (2) 2
female (2) 2
follow-up studies (2) 2
hematologi (2) 2
hemic and lymphatic diseases (2) 2
imatinib mesylate (2) 2
index medicus (2) 2
klinisk medicin (2) 2
male (2) 2
middle aged (2) 2
neoplasms (2) 2
piperazines - adverse effects (2) 2
piperazines - therapeutic use (2) 2
pyrimidines - adverse effects (2) 2
pyrimidines - therapeutic use (2) 2
treatment outcome (2) 2
abl tyrosine kinase (1) 1
abridged index medicus (1) 1
acute lymphoblastic-leukemia (1) 1
acute myeloid-leukemia (1) 1
acute promyelocytic leukemia (1) 1
adult (1) 1
age of onset (1) 1
aged (1) 1
alanine transaminase - blood (1) 1
algorithms (1) 1
alpha plus cytarabine (1) 1
antineoplastic agents - chemical synthesis (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
autoimmune hepatitis (1) 1
blast crisis (1) 1
blood coagulation - drug effects (1) 1
bms-354825 (1) 1
bone marrow (1) 1
budesonide (1) 1
budesonide - adverse effects (1) 1
budesonide - pharmacokinetics (1) 1
budesonide - therapeutic use (1) 1
cancer (1) 1
cancer research (1) 1
cells (1) 1
chronic active hepatitis (1) 1
chronic granulocytic-leukemia (1) 1
chronic lymphocytic-leukemia (1) 1
chronic myeloid leukemia (1) 1
chronic-phase (1) 1
clinical trials (1) 1
clinical trials and observations (1) 1
cml (1) 1
combined modality therapy - economics (1) 1
combined modality therapy - methods (1) 1
complete cytogenetic remission (1) 1
consensus (1) 1
corticosteroid-therapy (1) 1
crohns-disease (1) 1
cytarabine - administration & dosage (1) 1
cytogenetic analysis (1) 1
dasatinib (1) 1
disease-free survival (1) 1
dna mutational analysis (1) 1
dosage and administration (1) 1
drug therapy (1) 1
europe (1) 1
fusion proteins, bcr-abl - blood (1) 1
fusion proteins, bcr-abl - genetics (1) 1
gastroenterology & hepatology (1) 1
gene expression profiling (1) 1
genetic therapy - economics (1) 1
genetic therapy - methods (1) 1
genome, human (1) 1
health services for the aged - supply & distribution (1) 1
hematologic diseases - diagnosis (1) 1
hematologic diseases - economics (1) 1
hematologic diseases - pathology (1) 1
hematologic diseases - therapy (1) 1
hematology - economics (1) 1
hematology - methods (1) 1
hematopoiesis - drug effects (1) 1
hematopoiesis - genetics (1) 1
hematopoietic stem cell transplantation - methods (1) 1
hemolytic-uremic syndrome (1) 1
hepatitis, autoimmune - drug therapy (1) 1
inflammatory-bowel-disease (1) 1
inhibitors (1) 1
interferon (1) 1
interferon alpha (1) 1
interferon-alpha (1) 1
interferon-alpha - administration & dosage (1) 1
kaplan-meier estimate (1) 1
kinase domain mutations (1) 1
leukemia (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 02/2012, Volume 119, Issue 5, pp. 1123 - 1129
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2006, Volume 355, Issue 23, pp. 2408 - 2417
The constitutively active BCR-ABL tyrosine kinase is the cause of chronic myeloid leukemia. Imatinib is the first small synthetic molecular inhibitor of the... 
CHRONIC MYELOGENOUS LEUKEMIA | CELLS | MEDICINE, GENERAL & INTERNAL | CHRONIC GRANULOCYTIC-LEUKEMIA | INTERFERON-ALPHA | CHRONIC-PHASE | ABL TYROSINE KINASE | COMPLETE CYTOGENETIC REMISSION | PHILADELPHIA-CHROMOSOME | BLAST CRISIS | ALPHA PLUS CYTARABINE | Follow-Up Studies | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - adverse effects | Fusion Proteins, bcr-abl - blood | Female | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Kaplan-Meier Estimate | Survival Rate | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Cytarabine - administration & dosage | Interferon-alpha - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Survival Analysis | Benzamides | Protein-Tyrosine Kinases - antagonists & inhibitors | Dosage and administration | Chronic myeloid leukemia | Drug therapy | Interferon alpha | Clinical trials | Bone marrow | Transplants & implants | Pharmaceutical industry | Leukemia | Medical and Health Sciences | MEDICINE | Medicin och hälsovetenskap | MEDICIN
Journal Article
Haematologica, ISSN 0390-6078, 02/2016, Volume 101, Issue 2, pp. 115 - 208
Journal Article
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 21, pp. 2731 - 2731
Background Imatinib and dasatinib modulate immune responses in vitro and in vivo. Immunological surveillance in the MRD-situation might be of particular... 
Journal Article
Haematologica, ISSN 0390-6078, 02/2016, Volume 101, Issue 2, pp. 115 - 208
The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders... 
Clinical Medicine | Medical and Health Sciences | Hematology | Hematologi | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.